<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Trials</journal-id><journal-id journal-id-type="iso-abbrev">Trials</journal-id><journal-title-group><journal-title>Trials</journal-title></journal-title-group><issn pub-type="epub">1745-6215</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5698923</article-id><article-id pub-id-type="publisher-id">2233</article-id><article-id pub-id-type="doi">10.1186/s13063-017-2233-8</article-id><article-categories><subj-group subj-group-type="heading"><subject>Study Protocol</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Comparison of the effect of high versus low mean arterial pressure levels on clinical outcomes and complications in elderly patients during non-cardiothoracic surgery under general anesthesia: study protocol for a randomized controlled trial </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hu</surname><given-names>Anmin</given-names></name><address><email>toanmin@163.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Qiu</surname><given-names>Yan</given-names></name><address><email>12395299@qq.com</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Peng</given-names></name><address><email>583559085@qq.com</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Hu</surname><given-names>Bailong</given-names></name><address><email>375896605@qq.com</email></address><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Yali</given-names></name><address><email>yangyali_1982@163.com</email></address><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Shutao</given-names></name><address><email>cm_lst@163.com</email></address><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Rui</given-names></name><address><email>635741914@qq.com</email></address><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Zhang</surname><given-names>Zhongjun</given-names></name><address><email>luckydoczhang@163.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Yaoxian</given-names></name><address><email>19443322@qq.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Zheng</surname><given-names>Zihao</given-names></name><address><email>448337777@qq.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Qiu</surname><given-names>Chen</given-names></name><address><email>szchester@163.com</email></address><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Furong</given-names></name><address><email>frli62@163.com</email></address><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Gong</surname><given-names>Xiaolei</given-names></name><address><email>455949553@qq.com</email></address><xref ref-type="aff" rid="Aff10">10</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.440218.b</institution-id><institution>Department of Anesthesiology, </institution><institution>Shenzhen People’s Hospital, </institution></institution-wrap>Shenzhen, 518001 China </aff><aff id="Aff2"><label>2</label>Shenzhen Anesthesiology Engineering Center, Shenzhen, 518001 China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1790 3548</institution-id><institution-id institution-id-type="GRID">grid.258164.c</institution-id><institution>The Second Clinical Medical College, </institution><institution>Jinan University, </institution></institution-wrap>Shenzhen, 518001 China </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1770 1022</institution-id><institution-id institution-id-type="GRID">grid.412901.f</institution-id><institution>Department of Anesthesiology and Translational Neuroscience Center, </institution><institution>West China Hospital, Sichuan University, </institution></institution-wrap>Chengdu, 610000 China </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1808 0950</institution-id><institution-id institution-id-type="GRID">grid.410646.1</institution-id><institution>Department of Anesthesiology, </institution><institution>Sichuan Academy of Medical Sciences &amp; Sichuan Provincial People’s Hospital, </institution></institution-wrap>Chengdu, 610072 China </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="GRID">grid.452244.1</institution-id><institution>Department of Anesthesiology, </institution><institution>Affiliated Hospital of Guizhou Medical University, </institution></institution-wrap>Guiyang, 550004 China </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="GRID">grid.414011.1</institution-id><institution>Department of Anesthesiology, </institution><institution>Henan Provincial People’s Hospital of Zhengzhou University, </institution></institution-wrap>Zhengzhou, 450000 China </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1799 2448</institution-id><institution-id institution-id-type="GRID">grid.443573.2</institution-id><institution>Department of Anesthesiology, </institution><institution>Taihe Hospital of Hubei University of Medicine, </institution></institution-wrap>Shiyan, Hubei 442000 People’s Republic of China </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="GRID">grid.452826.f</institution-id><institution>Department of Anesthesiology, </institution><institution>The Third Affiliated Hospital of Kunming Medical University, </institution></institution-wrap>Kunming, 650106 China </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1790 3548</institution-id><institution-id institution-id-type="GRID">grid.258164.c</institution-id><institution>Clinical Medical Research Center, </institution><institution>The Second Clinical Medicine College, Jinan University, </institution></institution-wrap>Shenzhen, 518001 China </aff></contrib-group><pub-date pub-type="epub"><day>21</day><month>11</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>21</day><month>11</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>18</volume><elocation-id>554</elocation-id><history><date date-type="received"><day>19</day><month>12</month><year>2016</year></date><date date-type="accepted"><day>4</day><month>10</month><year>2017</year></date></history><permissions><copyright-statement>© The Author(s). 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title><text><SENT sid="1" pm="."><plain>Background </plain></SENT>
</text></title><p id="Par1"><SecTag type="ABS"><text><SENT sid="2" pm="."><plain>Intraoperative blood pressure (BP) is a concern in daily clinic anesthesia and contributes to the differences in clinical outcome. </plain></SENT>
<SENT sid="3" pm="."><plain>We conducted a randomized controlled trial (RCT) to compare the effect of high vs. low mean arterial pressure (MAP) levels on clinical outcomes and complications in elderly patients under general anesthesia (GA). </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="4" pm="."><plain>Methods </plain></SENT>
</text></title><p id="Par2"><SecTag type="ABS"><text><SENT sid="5" pm="."><plain>In this multicenter, randomized, parallel-controlled, open-label, assessor-blinded clinical trial, 322 patients aged more than 65 years will be randomized for a low-level MAP (60–70 mmHg) or high-level MAP (90–100 mmHg) during non-cardiothoracic surgery under GA. </plain></SENT>
<SENT sid="6" pm="."><plain>The primary outcome will be the incidence of postoperative delirium. </plain></SENT>
<SENT sid="7" pm="."><plain>The secondary outcomes will include the delirium duration days, intraoperative urine volume, intraoperative blood loss, specific postoperative complications, and all-cause 28-day mortality. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="8" pm="."><plain>Discussion </plain></SENT>
</text></title><p id="Par3"><SecTag type="ABS"><text><SENT sid="9" pm="."><plain>Results of this trial will help clarify whether BP management is beneficial for elderly patients under GA and will make clear whether the effect of high-level MAP can reduce the postoperative complication compared to low-level MAP. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="10" pm="."><plain>Trial registration </plain></SENT>
</text></title><p id="Par4"><SecTag type="ABS"><text><SENT sid="11" pm="."><plain>ClinicalTrials.gov, <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02857153?term=02857153&amp;rank=1">NCT02857153</ext-link>. </plain></SENT>
<SENT sid="12" pm="."><plain>Registered on 15 July 2016. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="13" pm="."><plain>Electronic supplementary material </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="14" pm="."><plain>The online version of this article (doi:10.1186/s13063-017-2233-8) contains supplementary material, which is available to authorized users. </plain></SENT>
</text></SecTag></p></sec></abstract><SecTag type="KEYWORD"><kwd-group xml:lang="en"><title>Keywords</title><kwd>Mean arterial pressure</kwd><kwd>General anesthesia</kwd><kwd>Postoperative complication</kwd><kwd>Elderly patients</kwd></kwd-group></SecTag><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>© The Author(s) 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><SecTag type="INTRO"><sec id="Sec1" sec-type="introduction"><title><text><SENT sid="15" pm="."><plain>Background </plain></SENT>
</text></title><p id="Par42"><text><SENT sid="16" pm="."><plain>Population ageing worldwide is rapidly accelerating from 461 million people aged over 65 years in 2004 to an estimated 2 billion people by 2050 [1, 2]. </plain></SENT>
<SENT sid="17" pm="."><plain>Many studies in elderly persons show an association between the presence of low blood pressure (BP) and adverse outcomes, including increased cognitive impairment [3, 4], risk of dementia [5], and mortality [6, 7]. </plain></SENT>
<SENT sid="18" pm="."><plain>Periprocedural BP could have been influenced by anesthetic management and contributed to the differences in clinical outcome [8–12]. </plain></SENT>
</text></p><p id="Par43"><text><SENT sid="19" pm="."><plain>Hypotension has the potential to cause an ischemia-reperfusion injury which may manifest as dysfunction of any vital organ. </plain></SENT>
<SENT sid="20" pm="."><plain>Among the most sensitive organs to be affected in this way are the brain, kidney, and heart. </plain></SENT>
<SENT sid="21" pm="."><plain>Low intraoperative mean arterial pressure (MAP) is associated with increased postoperative delirium [13], risk of stroke [14], acute kidney injury [15], myocardial infarction [15, 16], and 30-day mortality [17–20]. </plain></SENT>
<SENT sid="22" pm="."><plain>In 101 femoral neck fracture patients aged more than 65 years under spinal anesthesia, patients who developed postoperative delirium (PD) had perioperative falls in BP after surgery [13]. </plain></SENT>
<SENT sid="23" pm="."><plain>A MAP &lt; 60 mmHg and a relative decrease in MAP of 40% or more from the pre-induction BP is associated with postoperative myocardial injury if the decrease persists for more than 30 cumulative minutes [16]. </plain></SENT>
<SENT sid="24" pm="."><plain>MAP &lt; 55 mmHg was associated with the development of postoperative acute kidney and myocardial injuries [15]. </plain></SENT>
<SENT sid="25" pm="."><plain>Terri et al. reported that a significantly increased risk of 30-day mortality with a MAP ≤ 49 mmHg or MAP decreased to more than 50% from baseline for ≥ 5 min [18]. </plain></SENT>
</text></p><p id="Par44"><text><SENT sid="26" pm="."><plain>An important aspect of intervention to decrease postoperative complications is intraoperative BP management under general anesthesia (GA). </plain></SENT>
<SENT sid="27" pm="."><plain>Hypotension is recognized as an important factor in postoperative complications, but what BPs are unsafe is unclear in elderly patients. </plain></SENT>
<SENT sid="28" pm="."><plain>We designed this study to conduct a randomized controlled trial (RCT) to compare the effect of high vs. low MAP level on clinical outcomes and complications in elderly patients under GA. </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec id="Sec2" sec-type="materials|methods"><title><text><SENT sid="29" pm="."><plain>Methods </plain></SENT>
</text></title><sec id="Sec3"><title><text><SENT sid="30" pm="."><plain>Trial design </plain></SENT>
</text></title><p id="Par45"><text><SENT sid="31" pm="."><plain>This will be a multicenter, open-label, prospective RCT. </plain></SENT>
<SENT sid="32" pm="."><plain>Elderly patients will be included from seven centers, including Shenzhen People’s Hospital affiliated to Jinan University, West China Hospital affiliated to Sichuan University, The Affiliated Hospital of Guizhou Medical University, Taihe Hospital affiliated to Hubei University of Medicine, The Third Affiliated Hospital of Kunming Medical University, Sichuan Provincial People’s Hospital, and Henan Provincial People’s Hospital. </plain></SENT>
<SENT sid="33" pm="."><plain>All participants provided their written informed consent to participate in a RCT that examined the effects of low-level MAP (60–70 mmHg) vs. high-level MAP (90–100 mmHg) in elderly patients (aged 65 years or more) during non-cardiothoracic surgery under GA (trial registered at ClinicalTrials.gov under registration number: NCT02857153). </plain></SENT>
<SENT sid="34" pm="."><plain>MAP was calculated from the standard equation MAP = (2/3) diastolic blood pressure (DBP) + (1/3) systolic blood pressure (SBP) (in mmHg). </plain></SENT>
<SENT sid="35" pm="."><plain>We hypothesize high-level BP of the intervention for reducing the incidence of postoperative complications. </plain></SENT>
</text></p><p id="Par46"><text><SENT sid="36" pm="."><plain>This study protocol was written in accordance with the Standardized Protocol Interventions: Recommendations for Interventional Trials (SPIRIT) 2013 Statement (see Additional file 1 for the completed SPIRIT checklist) [21]. </plain></SENT>
<SENT sid="37" pm="."><plain>The time schedule of enrollment, assessment, interventions, and follow-up according to SPIRIT guidelines can be found in Fig. 1.Fig. 1The schedule of enrollment, interventions, and assessments </plain></SENT>
</text></p></sec><sec id="Sec4"><title><text><SENT sid="38" pm="."><plain>Patient population and eligibility criteria </plain></SENT>
</text></title><p id="Par47"><text><SENT sid="39" pm="."><plain>Patient eligibility is assessed at the preoperative anesthesia consultation. </plain></SENT>
<SENT sid="40" pm="."><plain>All eligible patients must sign a specifically designed informed consent form. </plain></SENT>
</text></p><p id="Par48"><text><SENT sid="41" pm="."><plain>Inclusion criteria are: men and women; American Society of Anesthesiologists (ASA) I–II; aged 65 years or more; scheduled to undergo non-cardiothoracic surgery with GA; and 2 h or more of scheduled surgery time. </plain></SENT>
</text></p><p id="Par49"><text><SENT sid="42" pm="."><plain>Participants will be excluded if they meet any of the following conditions: (1) the patient suffered from cardiovascular disease and metabolic diseases, such as hypertension, cardiac diseases, diabetes; (2) the patient has severe liver, kidney, or blood disease; (3) the patient is accompanied severe cognitive impairment (Mini-Mental State Examination [MMSE] score &lt; 15) [22]; (4) preoperative history of schizophrenia, epilepsy, parkinsonism, use of cholinesterase inhibitor, or levodopa treatment; use of haloperidol or other neuroleptics during or after anesthesia; (5) neurosurgery; (6) individuals unlikely to survive for &gt; 24 h; (7) previous participation in this study. </plain></SENT>
</text></p><p id="Par50"><text><SENT sid="43" pm="."><plain>Trial schematic diagram is shown in Fig. 2.Fig. 2Trial flow chart </plain></SENT>
</text></p></sec><sec id="Sec5"><title><text><SENT sid="44" pm="."><plain>Randomization and blinding </plain></SENT>
</text></title><p id="Par51"><text><SENT sid="45" pm="."><plain>Once consent is provided, participants will be assigned by the research assistant to either the low-level MAP group or high-level MAP group according to a random allocation sequence. </plain></SENT>
<SENT sid="46" pm="."><plain>An online random list generation will be utilized to perform blocked randomization in a 1 : 1 ratio. </plain></SENT>
<SENT sid="47" pm="."><plain>Trials cannot be blinded to anesthesiologist because anesthesiologist must know the MAP target to which each participant has been assigned in order to make the proper adjustment in the therapy to achieve 60–70 mmHg or 90–100 mmHg MAP. </plain></SENT>
<SENT sid="48" pm="."><plain>Outcome assessment and statistical analyses will be performed by independent researchers. </plain></SENT>
<SENT sid="49" pm="."><plain>Outcome assessor and the surgical team will be blinded to the study allocation status of participants. </plain></SENT>
</text></p></sec><sec id="Sec6"><title><text><SENT sid="50" pm="."><plain>Intervention </plain></SENT>
</text></title><p id="Par52"><text><SENT sid="51" pm="."><plain>On the day of surgery, patients come to the operating room and are provided with standard monitoring (electrocardiogram, oxygen saturation, non-invasive blood pressure, and invasive pressure monitoring). </plain></SENT>
<SENT sid="52" pm="."><plain>GA is given using midazolam (0.04 mg.kg–1) and propofol (as deemed appropriate by the anesthesiologist), opioids (fentanyl 3–6 μg.kg–1 and remifentanil 0.1–0.5 μg.kg–1.min–1), muscle relaxants (cisatracurium/rocuronium), and maintained with sevoflurane with inhaled concentrations of 1.5% sevoflurane in oxygen. </plain></SENT>
<SENT sid="53" pm="."><plain>Supplemental dosing of 1 μg.kg–1 of fentanyl is used every hour from induction up to approximately 1 h prior to the end of surgery. </plain></SENT>
<SENT sid="54" pm="."><plain>A tramadol bolus of 2 mg.kg–1 is given 15–30 min before the end of surgery. </plain></SENT>
<SENT sid="55" pm="."><plain>Propofol infusion is stopped 5–10 min before the end of surgery, whereas at the end of skin closure, remifentanil was discontinued. </plain></SENT>
</text></p><p id="Par53"><text><SENT sid="56" pm="."><plain>According to grouping, MAP is regulated to the goal level (60–70 mmHg or 95–100 mmHg) during GA. </plain></SENT>
<SENT sid="57" pm="."><plain>If necessary, intravenous anti-hypertensives (urapidil [0.2–0.5 mg.kg–1] or phenylephrine [4–6 μg.kg–1] when MAP exceeds 10 mmHg of the target value), rather than more anesthesia, may be used in situations wherein sympathetic stimulation is high; yet a sufficient amount of anesthesia is administered and bispectral index (BIS) shows an adequate depth of hypnosis. </plain></SENT>
<SENT sid="58" pm="."><plain>Sedation is provided by a propofol infusion targeted to a BIS number of approximately 50 during GA. </plain></SENT>
<SENT sid="59" pm="."><plain>Atropine (5–10 μg.kg–1) and esmolol (1–3 mg.kg–1) would be used at the time of heart rate &lt; 50 beats.min–1 and &gt; 110 beats.min–1, respectively. </plain></SENT>
</text></p><p id="Par54"><text><SENT sid="60" pm="."><plain>Lactated Ringer’s solution is given to bring the maintenance fluids to 10 mL.kg–1.h–1 [23]. </plain></SENT>
<SENT sid="61" pm="."><plain>Blood loss could be corrected for in a 1 : 1 ratio using gelofusine. </plain></SENT>
<SENT sid="62" pm="."><plain>Hospital transfusion guidelines are used to determine whether blood products are necessary (hemoglobin [HB] level &lt; 10 g.dl–1 in patients with cardiac co-morbidities and &lt; 7 g.dl–1 in those without cardiac disease). </plain></SENT>
<SENT sid="63" pm="."><plain>For later starting cases, an additional bolus of Ringer’s solution of 1.5 mL/kg/fasted hour from 08:00 is given to bring the total to 2 mL/kg/fasted hour. </plain></SENT>
<SENT sid="64" pm="."><plain>If urine output decreases to &lt; 0.5 mL.kg–1.h–1 for 1 h, fursemide 0.3 mg.kg–1 is given. </plain></SENT>
</text></p><p id="Par55"><text><SENT sid="65" pm="."><plain>Mechanical ventilation patterns are adjusted to obtain an end-tidal carbon dioxide value of 35–45 mmHg at 5–10 min after induction of anesthesia. </plain></SENT>
</text></p><p id="Par56"><text><SENT sid="66" pm="."><plain>For patients with endotracheal tubes, intravenous sedatives including propofol or midazolam were administrated continuously and titrated by bedside nurses to a target sedation level (Richmond Agitation Sedation Scale [RASS] range, – 2 to + 1) [24]. </plain></SENT>
<SENT sid="67" pm="."><plain>Daily awakening is used for those who were not extubated in the morning. </plain></SENT>
</text></p><p id="Par57"><text><SENT sid="68" pm="."><plain>All patients receive patient controlled intravenous analgesia (PCIA) during postoperative days 1–3. </plain></SENT>
<SENT sid="69" pm="."><plain>Patients would be given PCIA with fentanyl 5 μg.mL–1, tramadol 5 mg.mL–1, and tropisetron 50 μg.mL–1. </plain></SENT>
<SENT sid="70" pm="."><plain>The PCIA is programmed to deliver a bolus dose of 2 mL, with background infusion of 2 mL/h and a lockout of 5 min, with a 1-h limit of 10 mL. </plain></SENT>
</text></p></sec><sec id="Sec7"><title><text><SENT sid="71" pm="."><plain>Data collection </plain></SENT>
</text></title><p id="Par58"><text><SENT sid="72" pm="."><plain>We will collect outcomes relating to four levels of specification of outcome measures as proposed by Zarin et al. [25]: domain (for example, postoperative delirium); specific metric (for example, RASS); specific metric used to characterize each participant’s results (for example, the incidence within the seven-day period after surgery); and method of aggregation (for example, mean change and 95% confidence interval). </plain></SENT>
</text></p><p id="Par59"><text><SENT sid="73" pm="."><plain>A research assistant will collect date elements from patient medical records, including: </plain></SENT>
</text></p><p id="Par60"><text><SENT sid="74" pm="."><plain>Demographic data:&gt; data of birth;&gt; gender;&gt; preoperative diagnosis;&gt; previous treatments;&gt; co-morbid conditions;&gt; preoperative vital signs: pulse (P), BP, respiratory rate (R);&gt; baseline laboratory tests: aspartate transaminase (AST), alanine aminotransferase (ALT), blood urea nitrogen (BUN), serum creatinine (CREA), C-reactive protein (CRP), creatine kinase (CK), creatine kinase isoenzymes (CK-MB), brain natriuretic peptide (BNP), HB, white blood cell (WBC), platelet (PLT), oxygenation index (PaO2/FiO2), arterial carbon dioxide pressure (PaCO2), total bilirubin and fractions, prothrombin time (PT), activated partial thromboplastin time (APTT), international normalized ratio (INR);&gt; preoperative electrocardiogram;&gt; the ASA classification for preoperative health assessment of surgical patients [26]. </plain></SENT>
</text></p><p id="Par70"><text><SENT sid="75" pm="."><plain>Operative information:&gt; name of surgical operation;&gt; participation of fellow, resident, or medical student/clinical clerk in the surgical team;&gt; intraoperative blood loss;&gt; transfusion of blood products (packed red blood cells, platelets, fresh frozen plasma, albumin) and number of units;&gt; volume of intravenous crystalloid infusion;&gt; intraoperative urine volume;&gt; intraoperative drug dosage, including in urapidil, phenylephrine and fursemide;&gt; duration of surgery (defined as the number of hours between skin incision and closure of skin). </plain></SENT>
</text></p></sec><sec id="Sec8"><title><text><SENT sid="76" pm="."><plain>Laboratory analyses </plain></SENT>
</text></title><p id="Par79"><text><SENT sid="77" pm="."><plain>Preoperative values of laboratory tests (AST, ALT, BUN, CREA, CRP, CK, CK-MB, BNP, HB, WBC, PLT, PaO2/FiO2 and PaCO2) performed within the last week before surgery will be used as baseline values (before surgery). </plain></SENT>
<SENT sid="78" pm="."><plain>Additional blood samples will be collected on postoperative day 1 for serial laboratory evaluation. </plain></SENT>
</text></p></sec><sec id="Sec9"><title><text><SENT sid="79" pm="."><plain>Postoperative complications </plain></SENT>
</text></title><p id="Par80"><text><SENT sid="80" pm="."><plain>An independent board-certified physician will be the outcome assessor. </plain></SENT>
<SENT sid="81" pm="."><plain>He will be instructed about diagnostic criteria for specific postoperative complications in this trial. </plain></SENT>
<SENT sid="82" pm="."><plain>The outcome assessor will evaluate all participants until 28 days after surgery. </plain></SENT>
</text></p><p id="Par81"><text><SENT sid="83" pm="."><plain>Diagnostic criteria for specific postoperative complications:&gt; postoperative cognitive impairment defined by the confusion assessment method for the intensive care unit (CAM-ICU) [27]. </plain></SENT>
<SENT sid="84" pm="."><plain>First, level of sedation (level of arousal) was assessed using the RASS. </plain></SENT>
<SENT sid="85" pm="."><plain>If the patient was deeply sedated or was unarousable (– 4 or – 5 on the RASS), then assessment was stopped and repeated later, and the patient was noted as comatose. </plain></SENT>
<SENT sid="86" pm="."><plain>If RASS was &gt; – 4 (– 3 through + 4), then assessment was continued to the next step. </plain></SENT>
<SENT sid="87" pm="."><plain>Second, delirium was diagnosed using CAM-ICU. </plain></SENT>
<SENT sid="88" pm="."><plain>It detects four features of delirium: acute onset of mental status changes or a fluctuating course; inattention; disorganized thinking; and altered level of consciousness. </plain></SENT>
<SENT sid="89" pm="."><plain>To have delirium diagnosed, a patient must display the first two aforementioned features, with either the third or fourth aforementioned feature;&gt; hemorrhage: if requiring reoperation, radiological or endoscopic intervention; information on postoperative transfusion of blood products (type and number of units) will also be collected;&gt; arrhythmias: any change in cardiac sinus rhythm prompting specific medical intervention or patient transfer to a monitored bed;&gt; pulmonary embolism: confirmed by computed tomography (CT);&gt; deep venous thrombosis: confirmed by Doppler ultrasonography;&gt; acute liver failure: confirmed by physical exam, laboratory findings, patient history, and past medical history to establish mental status changes, coagulopathy, rapidity of onset, and absence of known prior liver disease, respectively [28];&gt; acute kidney injury: defined by the Kidney Disease: Improving Global Outcomes (KDIGO) creatinine-based criteria [29];&gt; all cases of acute myocardial infarction, cerebrovascular accident, or transient ischemic attack, as diagnosed by appropriate medical specialist;&gt; other: any unlisted postoperative complications requiring specific medical treatment, radiological intervention or reoperation. </plain></SENT>
</text></p></sec><sec id="Sec10"><title><text><SENT sid="90" pm="."><plain>Study outcomes </plain></SENT>
</text></title><p id="Par91"><text><SENT sid="91" pm="."><plain>Primary outcome measure: </plain></SENT>
</text></p><p id="Par92"><text><SENT sid="92" pm="."><plain>The incidence of PD within the seven-day period after surgery. </plain></SENT>
<SENT sid="93" pm="."><plain>Patients will be assessed for delirium with the CAM-ICU twice daily (at 08:00–10:00 and 18:00–20:00) during the first seven days after surgery. </plain></SENT>
</text></p><p id="Par93"><text><SENT sid="94" pm="."><plain>Secondary outcomes:Delirium duration days during the seven-day period after surgery.Intraoperative urine volume.Intraoperative blood loss: estimated using loss of red cell mass, which was derived from differences in pre- and postoperative hematocrits and transfused red cell mass with the following equation [30]: loss of red cell mass (mL)  =  estimated blood volume of patient (mL)  ×  (preoperative hematocrit (%) − immediate postoperative hematocrit (%))/100 + (transfused packed RBCs [unit]  ×  213  ×  0.7) (estimated blood volume of patient [mL]  =  75 mL/kg for men or 65 mL/kg for women  ×  body weight [kg]; 213 mL for average volume of packed RBC; 0.7 value for hematocrit of packed RBCs).Specific postoperative complications within the seven-day period after surgery, including in bleeding requiring intervention, arrhythmias, pulmonary embolism, deep venous thrombosis, acute liver failure, acute kidney injury, acute myocardial infarction, cerebrovascular accident, or transient ischemic attack.All-cause 28-day mortality. </plain></SENT>
</text></p></sec><sec id="Sec11"><title><text><SENT sid="95" pm="."><plain>Adverse events </plain></SENT>
</text></title><p id="Par99"><text><SENT sid="96" pm="."><plain>Serious adverse events and other untoward events that require hospitalization, are life-threatening, or result in death are collected following the SPIRIT recommendations [21]. </plain></SENT>
<SENT sid="97" pm="."><plain>All adverse events will be recorded and closely monitored until resolution or stabilization or until it has been shown that the study treatment is not the cause of the event. </plain></SENT>
<SENT sid="98" pm="."><plain>The Chief Investigator will be informed immediately of any serious adverse events and will determine (in cooperation with the treating medical practitioners) the seriousness and causality of these events. </plain></SENT>
<SENT sid="99" pm="."><plain>All treatment-related serious adverse events will be recoded and reported to the research Ethics Committee as part of the report. </plain></SENT>
<SENT sid="100" pm="."><plain>Unexpected serious adverse events will be reported to the research Ethics Committee within the relevant time frames. </plain></SENT>
<SENT sid="101" pm="."><plain>The Chief Investigator will be responsible for all adverse event reporting. </plain></SENT>
<SENT sid="102" pm="."><plain>All site staff will be appropriately trained in the procedures to follow and the forms to use during the study protocol before study initiation. </plain></SENT>
<SENT sid="103" pm="."><plain>If serious side-effects occur, the Chief Investigator can then unblended the participant and give the patient post-trial care. </plain></SENT>
</text></p></sec><sec id="Sec12"><title><text><SENT sid="104" pm="."><plain>Withdrawal and dropout </plain></SENT>
</text></title><p id="Par100"><text><SENT sid="105" pm="."><plain>Participation in the study will end at any stage if the patient refuses to continue, withdraws consent, or violates inclusion or exclusion criteria or the trial protocol. </plain></SENT>
<SENT sid="106" pm="."><plain>The trial will be stopped if the principle investigator believes that there are unacceptable risks of serious adverse events. </plain></SENT>
<SENT sid="107" pm="."><plain>No interim analysis will be conducted; however, the Data Safety and Monitoring Committee (DSMC) will perform regular reviews of all study outcome and adverse event data to ensure that there is no difference in rates of hospitalization or exacerbation in either group. </plain></SENT>
<SENT sid="108" pm="."><plain>The DSMC will determine final criteria for early study termination, which may be based on clear-cut evidence of worsened safety in one of the trial arms, and in the case of evidence beyond reasonable doubt of clear-cut benefit in the primary outcome measure, an effect size which would change clinical practice in the presence of the current literature and understanding of the disease area. </plain></SENT>
</text></p></sec><sec id="Sec13"><title><text><SENT sid="109" pm="."><plain>Confidentiality </plain></SENT>
</text></title><p id="Par101"><text><SENT sid="110" pm="."><plain>On recruitment, the research assistant will give a unique scrambled study number to each participant. </plain></SENT>
<SENT sid="111" pm="."><plain>Only the study number will be used to identify participants. </plain></SENT>
<SENT sid="112" pm="."><plain>Data collection sheets and any printout of electronic files will be kept in a locked filing cabinet in a secure office with limited access. </plain></SENT>
<SENT sid="113" pm="."><plain>The master list of participants and informed consent forms will be securely stored separately from de-identified participant records. </plain></SENT>
<SENT sid="114" pm="."><plain>All digital files will be password protected and stored in a firewall protected secure environment. </plain></SENT>
<SENT sid="115" pm="."><plain>The trial sponsor has access to the final trial dataset. </plain></SENT>
</text></p></sec><sec id="Sec14"><title><text><SENT sid="116" pm="."><plain>Statistical analysis </plain></SENT>
</text></title><p id="Par102"><text><SENT sid="117" pm="."><plain>Postoperative delirium is a frequent complication after major surgery in elderly patients and is related to an increase in mortality [31]. </plain></SENT>
<SENT sid="118" pm="."><plain>Probability of first postoperative day PD in elderly hip fracture patients is in the range of 20–60% [9]. </plain></SENT>
<SENT sid="119" pm="."><plain>PD occurred in 44% of elderly patients after a major operation [31]. </plain></SENT>
<SENT sid="120" pm="."><plain>Our sample size was calculated to detect a 15% difference in PD between the two groups with a two-tailed test, a significance level (alpha) of 5%, and a power of 80%. </plain></SENT>
<SENT sid="121" pm="."><plain>The sample size calculation was performed on STATA 14.0 software (StataCorp, College Station, TX, USA). </plain></SENT>
<SENT sid="122" pm="."><plain>We plan to include a total of 322 participants. </plain></SENT>
</text></p><p id="Par103"><text><SENT sid="123" pm="."><plain>Analyses will be conducted at the Clinical Research Institute of Shenzhen People’s Hospital by blinded biostatisticians. </plain></SENT>
<SENT sid="124" pm="."><plain>Data analysis is on an intention-to-treat basis. </plain></SENT>
</text></p><p id="Par104"><text><SENT sid="125" pm="."><plain>The level of significance was set at 5% and statistical analysis was performed using GraphPad Prism version 6.02 for Windows (GraphPad Software, San Diego, CA, USA). </plain></SENT>
<SENT sid="126" pm="."><plain>Continuous variable will be summarized using means and SDs (normally distributed data) or medians and ranges (non-normally distributed data). </plain></SENT>
<SENT sid="127" pm="."><plain>We will perform group comparison by using the Student’s t test or Mann–Whitney test for quantitative variables and Pearson’s chi-squared test for categorical variable. </plain></SENT>
<SENT sid="128" pm="."><plain>The odds ratio and 95% confidence interval will be computed with logistic regression. </plain></SENT>
</text></p></sec><sec id="Sec15"><title><text><SENT sid="129" pm="."><plain>Trial oversight </plain></SENT>
</text></title><p id="Par105"><text><SENT sid="130" pm="."><plain>A Trial Management Group including the Chief Investigator, Trial Coordinator, Trial Manger, Data Manager and Trial Statistician are in contact weekly. </plain></SENT>
</text></p><p id="Par106"><text><SENT sid="131" pm="."><plain>A Trial Steering Committee (TSC) will meet at least three times each month over the Internet, and more frequently if required, to review the trial progress and to ensure that it is being conducted in accordance with the protocol, relevant regulations, and the principles of good clinical practice. </plain></SENT>
</text></p><p id="Par107"><text><SENT sid="132" pm="."><plain>A DSMC will review trial progress and safety data. </plain></SENT>
<SENT sid="133" pm="."><plain>The DSMC is independent of the trial investigators and will comprise three independent members including two clinical specialists and a trial statistician. </plain></SENT>
</text></p></sec><sec id="Sec16"><title><text><SENT sid="134" pm="."><plain>Protocol amendments </plain></SENT>
</text></title><p id="Par108"><text><SENT sid="135" pm="."><plain>Protocol amendments will be agreed upon with the TSC, DSMC, Sponsor and Funding Body before submission for ethical approval. </plain></SENT>
<SENT sid="136" pm="."><plain>Following ethical approval, protocol modifications will be communicated with relevant parties such as the trial investigators, the trial registry, and, if required, trial participants. </plain></SENT>
</text></p></sec><sec id="Sec17"><title><text><SENT sid="137" pm="."><plain>Dissemination policy </plain></SENT>
</text></title><p id="Par109"><text><SENT sid="138" pm="."><plain>The results of the trial will be widely disseminated to patients, health professionals, commissioners, policy makers, and the general public. </plain></SENT>
<SENT sid="139" pm="."><plain>Our patient public involvement members will play a key role in this. </plain></SENT>
<SENT sid="140" pm="."><plain>The trial results will be disseminated to a wide clinical audience through publication in a high impact international scientific journal. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="DISCUSS"><sec id="Sec18" sec-type="discussion"><title><text><SENT sid="141" pm="."><plain>Discussion </plain></SENT>
</text></title><p id="Par110"><text><SENT sid="142" pm="."><plain>Intraoperative MAP influences clinical outcomes [8, 9, 32]. </plain></SENT>
<SENT sid="143" pm="."><plain>Intraoperative hypotension has been implicated in ischemia-reperfusion injury to the brain, heart, and kidneys and is associated with death [15, 17, 20]. </plain></SENT>
<SENT sid="144" pm="."><plain>This multicenter, open-label, randomized, parallel-controlled clinical trial is designed to test the hypothesis that, compared with low-level MAP, high-level MAP under GA reduces postoperative complications in elderly patients during non-cardiothoracic surgery. </plain></SENT>
<SENT sid="145" pm="."><plain>Even a neutral result will provide an important insight, as this would mean that more studies are needed to explore a safe and effective way of blood pressure management during GA in elderly patients. </plain></SENT>
<SENT sid="146" pm="."><plain>This is the main strength of the present study. </plain></SENT>
</text></p><p id="Par111"><text><SENT sid="147" pm="."><plain>There are some limitations to our study protocol. </plain></SENT>
<SENT sid="148" pm="."><plain>First, a multicenter design is adopted so that patients enrolled in the study include a variety of surgical procedures under different clinical environments. </plain></SENT>
<SENT sid="149" pm="."><plain>This will increase the generalizability of our results. </plain></SENT>
<SENT sid="150" pm="."><plain>Because of the apparent difference between BP management, a double-blind design cannot be achieved. </plain></SENT>
<SENT sid="151" pm="."><plain>Therefore, we had to use an open-label design. </plain></SENT>
<SENT sid="152" pm="."><plain>The following measures will be undertaken to decrease the risk of potential bias. </plain></SENT>
<SENT sid="153" pm="."><plain>Second, there is evidence that intraoperative BP influence long-term consequences in elderly patients after GA [33]. </plain></SENT>
<SENT sid="154" pm="."><plain>However, our research is primarily concerned about the effects of low-level vs. high-level MAP on short-term postoperative complications. </plain></SENT>
<SENT sid="155" pm="."><plain>Third, patients who will be included as eligible participants should have no cardiovascular disease and metabolic diseases. </plain></SENT>
<SENT sid="156" pm="."><plain>Therefore, the results of this study will be restrainedly applied to all elderly patients during non-cardiothoracic surgery under GA. </plain></SENT>
</text></p><p id="Par112"><text><SENT sid="157" pm="."><plain>Appropriate BP management would improve patient outcomes. </plain></SENT>
<SENT sid="158" pm="."><plain>Strengths of the protocol include that it is the first multicenter and centrally randomized study and that it observes both the primary (the seven-day incidence of PD) and secondary endpoints (duration days of PD, intraoperative urine volume, intraoperative blood loss, specific postoperative complications, and all-cause 28-day mortality). </plain></SENT>
<SENT sid="159" pm="."><plain>Results of the study will provide evidence for chasing felicitous BP management in elderly patients during non-cardiothoracic surgery under GA. </plain></SENT>
</text></p><sec id="Sec19"><title><text><SENT sid="160" pm="."><plain>Trial status </plain></SENT>
</text></title><p id="Par113"><text><SENT sid="161" pm="."><plain>The trial is currently recruiting participants. </plain></SENT>
<SENT sid="162" pm="."><plain>To date (1 November 2016), 60 participants have been recruited. </plain></SENT>
<SENT sid="163" pm="."><plain>A report releasing study results will be submitted for publication in an appropriate journal, approximately 15 months after finishing data collection. </plain></SENT>
</text></p></sec></sec></SecTag></body><back><SecTag type="APPENDIX"><app-group><app id="App1"><sec id="Sec20"><title>Additional file</title><p id="Par117">
<media position="anchor" xlink:href="13063_2017_2233_MOESM1_ESM.pdf" id="MOESM1"><label>Additional file 1:</label><caption><p><text><SENT sid="164" pm="."><plain>SPIRIT checklist. </plain></SENT>
<SENT sid="165" pm="."><plain>Completed SPIRIT checklist. </plain></SENT>
<SENT sid="166" pm="."><plain>(PDF 97 kb) </plain></SENT>
</text></p></caption></media>
</p></sec></app></app-group></SecTag><SecTag type="ABBR"><glossary><title>Abbreviations</title><def-list><def-item><term>ALT</term><def><p id="Par5">Alanine aminotransferase</p></def></def-item><def-item><term>APTT</term><def><p id="Par6">Activated partial thromboplastin time</p></def></def-item><def-item><term>ASA</term><def><p id="Par7">American Society of Anesthesiologist</p></def></def-item><def-item><term>AST</term><def><p id="Par8">Aspartate transaminase</p></def></def-item><def-item><term>BIS</term><def><p id="Par9">Bispectral index</p></def></def-item><def-item><term>BNP</term><def><p id="Par10">Brain natriuretic peptide</p></def></def-item><def-item><term>BP</term><def><p id="Par11">Blood pressure</p></def></def-item><def-item><term>BUN</term><def><p id="Par12">Blood urea nitrogen</p></def></def-item><def-item><term>CAM-ICU</term><def><p id="Par13">Confusion assessment method for the intensive care unit</p></def></def-item><def-item><term>CK</term><def><p id="Par14">Creatine kinase</p></def></def-item><def-item><term>CK-MB</term><def><p id="Par15">Creatine kinase isoenzymes</p></def></def-item><def-item><term>CREA</term><def><p id="Par16">Serum creatinine</p></def></def-item><def-item><term>CRP</term><def><p id="Par17">C-reactive protein</p></def></def-item><def-item><term>CT</term><def><p id="Par18">Computed tomography</p></def></def-item><def-item><term>DBP</term><def><p id="Par19">Diastolic blood pressure</p></def></def-item><def-item><term>DSMC</term><def><p id="Par20">Data Safety and Monitoring Committee</p></def></def-item><def-item><term>GA</term><def><p id="Par21">General anesthesia</p></def></def-item><def-item><term>HB</term><def><p id="Par22">Hemoglobin</p></def></def-item><def-item><term>INR</term><def><p id="Par23">International normalized ratio</p></def></def-item><def-item><term>IRB</term><def><p id="Par24">Institutional Review Board</p></def></def-item><def-item><term>KDIGO</term><def><p id="Par25">Kidney Disease, Improving Global Outcomes</p></def></def-item><def-item><term>MAP</term><def><p id="Par26">Mean arterial pressure</p></def></def-item><def-item><term>MMSE</term><def><p id="Par27">Mini-Mental State Examination</p></def></def-item><def-item><term>P</term><def><p id="Par28">Pulse</p></def></def-item><def-item><term>PaCO2</term><def><p id="Par29">Arterial carbon dioxide pressure</p></def></def-item><def-item><term>PaO2/FiO2</term><def><p id="Par30">Oxygenation index</p></def></def-item><def-item><term>PCIA</term><def><p id="Par31">Controlled intravenous analgesia</p></def></def-item><def-item><term>PD</term><def><p id="Par32">Postoperative delirium</p></def></def-item><def-item><term>PLT</term><def><p id="Par33">Platelet</p></def></def-item><def-item><term>PT</term><def><p id="Par34">Prothrombin time</p></def></def-item><def-item><term>R</term><def><p id="Par35">Respiratory rate</p></def></def-item><def-item><term>RASS</term><def><p id="Par36">Richmond Agitation Sedation Scale</p></def></def-item><def-item><term>RCT</term><def><p id="Par37">Randomized controlled trial</p></def></def-item><def-item><term>SBP</term><def><p id="Par38">Systolic blood pressure</p></def></def-item><def-item><term>SPIRIT</term><def><p id="Par39">Standard Protocol Items, Recommendations for Interventional Trials</p></def></def-item><def-item><term>TSC</term><def><p id="Par40">Trial Steering Committee</p></def></def-item><def-item><term>WBC</term><def><p id="Par41">White blood cell</p></def></def-item></def-list></glossary></SecTag><fn-group><fn><p><text><SENT sid="167" pm="."><plain>Electronic supplementary material </plain></SENT>
</text></p><p><text><SENT sid="168" pm="."><plain>The online version of this article (doi:10.1186/s13063-017-2233-8) contains supplementary material, which is available to authorized users. </plain></SENT>
</text></p></fn></fn-group><SecTag type="ACK_FUND"><ack><title>Acknowledgements</title><p><text4fund><text><SENT sid="169" pm="."><plain>We thank the couples who participated in this study and the teams at the study sites and the University of Jinan for work on data collection and management. </plain></SENT>
<SENT sid="170" pm="."><plain>The current study is supported by a grant from Shenzhen People’s Hospital. </plain></SENT>
<SENT sid="171" pm="."><plain>No funding has been and will be received for the present trial. </plain></SENT>
</text></text4fund></p></ack></SecTag><SecTag type="SUPPL"><notes notes-type="author-contribution"><title>Authors’ contributions</title><p>HAM is responsible for developing the treatment protocol, carrying out and supervising the clinical study, and drafting the manuscript as a primary investigator. HAM and ZZJ conceived the study. GXL generated the computerized randomization schedule to reveal allocation. HAM, QY, ZP, HBL, YY, LST, and ZR enrolled the participants. ZZJ assigned participants to interventions. ZYX and ZZH analyzed the data. QC and LFR contribute to the design of the study and supervise the protocol fulfillment. All authors read and approved the final manuscript.</p></notes></SecTag><notes notes-type="COI-statement"><title>Ethics approval and consent to participate</title><p>This study is being conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice guidelines. The study was approved by a central ethics committee of Shenzhen People’s Hospital, Jinan University, China (Institutional Review Board number: 2016001) and filed in the seven centers (Shenzhen People’s Hospital, West China Hospital, Sichuan Provincial People’s Hospital, Affiliated Hospital of Guizhou Medical University, Henan Provincial People’s Hospital, Taihe Hospital, and The Third Affiliated Hospital of Kunming Medical University). Before randomization, written informed consent will be obtained from all participants. No expenses will be paid at all.</p><sec id="FPar1"><title>Consent for publication</title><p id="Par114">Written informed consent was obtained from the patient for publication of their individual details and accompanying images in this manuscript. The consent form is held by the authors and is available for review by the Editor-in-Chief. The study’s findings will be published in peer-reviewed journals.</p></sec><sec id="FPar2"><title>Competing interests</title><p id="Par115">The authors declare that they have no competing interests.</p></sec><sec id="FPar3"><title>Publisher’s Note</title><p id="Par116">Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></notes><SecTag type="REF"><ref-list id="Bib1"><title>References</title><ref id="CR1"><text><SENT sid="172" pm="."><plain>1.KinsellaKPhillipsDRGlobal aging: the challenge of successPopul Bull2005601340 </plain></SENT>
</text></ref><ref id="CR2"><text><SENT sid="173" pm="."><plain>2.LutzWSandersonWScherbovSThe coming acceleration of global population ageingNature20084517179716910.1038/nature06516<?supplied-pmid 18204438?>18204438 </plain></SENT>
</text></ref><ref id="CR3"><text><SENT sid="174" pm="."><plain>3.QiuCWinbladBFratiglioniLThe age-dependent relation of blood pressure to cognitive function and dementiaLancet Neurol2005484879910.1016/S1474-4422(05)70141-1<?supplied-pmid 16033691?>16033691 </plain></SENT>
</text></ref><ref id="CR4"><text><SENT sid="175" pm="."><plain>4.EuserSMvan BemmelTSchramMTGusseklooJHofmanAWestendorpRGThe effect of age on the association between blood pressure and cognitive function later in lifeJ Am Geriatr Soc20095771232710.1111/j.1532-5415.2009.02264.x<?supplied-pmid 19453303?>19453303 </plain></SENT>
</text></ref><ref id="CR5"><text><SENT sid="176" pm="."><plain>5.RuitenbergASkoogIOttAAevarssonOWittemanJCLernfeltBBlood pressure and risk of dementia: results from the Rotterdam study and the Gothenburg H-70 StudyDement Geriatr Cogn Disord200112133910.1159/000051233<?supplied-pmid 11125239?>11125239 </plain></SENT>
</text></ref><ref id="CR6"><text><SENT sid="177" pm="."><plain>6.KagiyamaSTakataYAnsaiTMatsumuraKSohIAwanoSDoes decreased diastolic blood pressure associate with increased mortality in 80-year-old Japanese?Clin Exp Hypertens20093186394710.3109/10641960903407009<?supplied-pmid 20001456?>20001456 </plain></SENT>
</text></ref><ref id="CR7"><text><SENT sid="178" pm="."><plain>7.MolanderLLovheimHNormanTNordstromPGustafsonYLower systolic blood pressure is associated with greater mortality in people aged 85 and olderJ Am Geriatr Soc200856101853910.1111/j.1532-5415.2008.01948.x<?supplied-pmid 18811610?>18811610 </plain></SENT>
</text></ref><ref id="CR8"><text><SENT sid="179" pm="."><plain>8.DavisMJMenonBKBaghirzadaLBCampos-HerreraCRGoyalMHillMDAnesthetic management and outcome in patients during endovascular therapy for acute strokeAnesthesiology2012116239640510.1097/ALN.0b013e318242a5d2<?supplied-pmid 22222475?>22222475 </plain></SENT>
</text></ref><ref id="CR9"><text><SENT sid="180" pm="."><plain>9.WangNYHiraoASieberFAssociation between intraoperative blood pressure and postoperative delirium in elderly hip fracture patientsPLoS One2015104e012389210.1371/journal.pone.0123892<?supplied-pmid 25860338?>25860338 </plain></SENT>
</text></ref><ref id="CR10"><text><SENT sid="181" pm="."><plain>10.LondonMJIntraoperative mean blood pressure and outcome: is 80 (mmHg) the “New” 60?Anesthesiology201612414610.1097/ALN.0000000000000923<?supplied-pmid 26540150?>26540150 </plain></SENT>
</text></ref><ref id="CR11"><text><SENT sid="182" pm="."><plain>11.TogashiKJoffeAMSekharLKimLLamAYanezDRandomized pilot trial of intensive management of blood pressure or volume expansion in subarachnoid hemorrhage (IMPROVES)Neurosurgery20157621253410.1227/NEU.0000000000000592<?supplied-pmid 25549192?>25549192 </plain></SENT>
</text></ref><ref id="CR12"><text><SENT sid="183" pm="."><plain>12.BentovIReedMJAnesthesia, microcirculation, and wound repair in agingAnesthesiology201412037607210.1097/ALN.0000000000000036<?supplied-pmid 24195972?>24195972 </plain></SENT>
</text></ref><ref id="CR13"><text><SENT sid="184" pm="."><plain>13.EdlundALundstromMBrannstromBBuchtGGustafsonYDelirium before and after operation for femoral neck fractureJ Am Geriatr Soc2001491013354010.1046/j.1532-5415.2001.49261.x<?supplied-pmid 11890492?>11890492 </plain></SENT>
</text></ref><ref id="CR14"><text><SENT sid="185" pm="."><plain>14.ChangHSHongoKNakagawaHAdverse effects of limited hypotensive anesthesia on the outcome of patients with subarachnoid hemorrhageJ Neurosurg2000926971510.3171/jns.2000.92.6.0971<?supplied-pmid 10839257?>10839257 </plain></SENT>
</text></ref><ref id="CR15"><text><SENT sid="186" pm="."><plain>15.WalshMDevereauxPJGargAXKurzATuranARodsethRNRelationship between intraoperative mean arterial pressure and clinical outcomes after noncardiac surgery: toward an empirical definition of hypotensionAnesthesiology201311935071510.1097/ALN.0b013e3182a10e26<?supplied-pmid 23835589?>23835589 </plain></SENT>
</text></ref><ref id="CR16"><text><SENT sid="187" pm="."><plain>16.van WaesJAvan KleiWAWijeysunderaDNvan WolfswinkelLLindsayTFBeattieWSAssociation between intraoperative hypotension and myocardial injury after vascular surgeryAnesthesiology20161241354410.1097/ALN.0000000000000922<?supplied-pmid 26540148?>26540148 </plain></SENT>
</text></ref><ref id="CR17"><text><SENT sid="188" pm="."><plain>17.SesslerDISiglJCKelleySDChamounNGManbergPJSaagerLHospital stay and mortality are increased in patients having a “triple low” of low blood pressure, low bispectral index, and low minimum alveolar concentration of volatile anesthesiaAnesthesiology20121166119520310.1097/ALN.0b013e31825683dc<?supplied-pmid 22546967?>22546967 </plain></SENT>
</text></ref><ref id="CR18"><text><SENT sid="189" pm="."><plain>18.MonkTGBronsertMRHendersonWGMangioneMPSum-PingSTBenttDRAssociation between intraoperative hypotension and hypertension and 30-day postoperative mortality in noncardiac surgeryAnesthesiology201512323071910.1097/ALN.0000000000000756<?supplied-pmid 26083768?>26083768 </plain></SENT>
</text></ref><ref id="CR19"><text><SENT sid="190" pm="."><plain>19.WillinghamMDKarrenEShanksAMO'ConnorMFJacobsohnEKheterpalSConcurrence of intraoperative hypotension, low minimum alveolar concentration, and low bispectral index is associated with postoperative deathAnesthesiology201512347758510.1097/ALN.0000000000000822<?supplied-pmid 26267244?>26267244 </plain></SENT>
</text></ref><ref id="CR20"><text><SENT sid="191" pm="."><plain>20.MonkTGSainiVWeldonBCSiglJCAnesthetic management and one-year mortality after noncardiac surgeryAnesth Analg2005100141010.1213/01.ANE.0000147519.82841.5E<?supplied-pmid 15616043?>15616043 </plain></SENT>
</text></ref><ref id="CR21"><text><SENT sid="192" pm="."><plain>21.ChanAWTetzlaffJMAltmanDGDickersinKMoherDSPIRIT 2013: new guidance for content of clinical trial protocolsLancet2013381986191210.1016/S0140-6736(12)62160-6<?supplied-pmid 23305999?>23305999 </plain></SENT>
</text></ref><ref id="CR22"><text><SENT sid="193" pm="."><plain>22.FolsteinMFFolsteinSEMcHughPR“Mini-mental state”. </plain></SENT>
<SENT sid="194" pm="."><plain>A practical method for grading the cognitive state of patients for the clinicianJ Psychiatr Res19751231899810.1016/0022-3956(75)90026-6<?supplied-pmid 1202204?>1202204 </plain></SENT>
</text></ref><ref id="CR23"><text><SENT sid="195" pm="."><plain>23.JacobMChappellDRehmMClinical update: perioperative fluid managementLancet200736995781984610.1016/S0140-6736(07)60926-X<?supplied-pmid 17574081?>17574081 </plain></SENT>
</text></ref><ref id="CR24"><text><SENT sid="196" pm="."><plain>24.SesslerCNGosnellMSGrapMJBrophyGMO'NealPVKeaneKAThe Richmond Agitation-Sedation Scale: validity and reliability in adult intensive care unit patientsAm J Respir Crit Care Med20021661013384410.1164/rccm.2107138<?supplied-pmid 12421743?>12421743 </plain></SENT>
</text></ref><ref id="CR25"><text><SENT sid="197" pm="."><plain>25.ZarinDATseTWilliamsRJCaliffRMIdeNCThe ClinicalTrials.gov results database–update and key issuesN Engl J Med201136498526010.1056/NEJMsa1012065<?supplied-pmid 21366476?>21366476 </plain></SENT>
</text></ref><ref id="CR26"><text><SENT sid="198" pm="."><plain>26.OwensWDFeltsJASpitznagelELJrASA physical status classifications: a study of consistency of ratingsAnesthesiology19784942394310.1097/00000542-197810000-00003<?supplied-pmid 697077?>697077 </plain></SENT>
</text></ref><ref id="CR27"><text><SENT sid="199" pm="."><plain>27.ElyEWMargolinRFrancisJMayLTrumanBDittusREvaluation of delirium in critically ill patients: validation of the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU)Crit Care Med20012971370910.1097/00003246-200107000-00012<?supplied-pmid 11445689?>11445689 </plain></SENT>
</text></ref><ref id="CR28"><text><SENT sid="200" pm="."><plain>28.FeldmanMFriedmanLSBrandtLJSleisenger and Fordtran’s Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management, Expert Consult Premium Edition - Enhanced Online Features2010New YorkElsevier </plain></SENT>
</text></ref><ref id="CR29"><text><SENT sid="201" pm="."><plain>29.BellomoRKellumJARoncoCDefining and classifying acute renal failure: from advocacy to consensus and validation of the RIFLE criteriaIntensive Care Med20073334091310.1007/s00134-006-0478-x<?supplied-pmid 17165018?>17165018 </plain></SENT>
</text></ref><ref id="CR30"><text><SENT sid="202" pm="."><plain>30.BangSRAhnHJKimGSYangMGwakMSKoJSPredictors of high intraoperative blood loss derived by simple and objective method in adult living donor liver transplantationTransplant Proc2010421041485010.1016/j.transproceed.2010.10.017<?supplied-pmid 21168648?>21168648 </plain></SENT>
</text></ref><ref id="CR31"><text><SENT sid="203" pm="."><plain>31.RobinsonTNRaeburnCDTranZVAnglesEMBrennerLAMossMPostoperative delirium in the elderly: risk factors and outcomesAnn Surg20092491173810.1097/SLA.0b013e31818e4776<?supplied-pmid 19106695?>19106695 </plain></SENT>
</text></ref><ref id="CR32"><text><SENT sid="204" pm="."><plain>32.TogashiKJoffeAMSekharLKimLLamAYanezDRandomized pilot trial of intensive management of blood pressure or volume expansion in subarachnoid hemorrhage (IMPROVES)Neurosurgery2015762134510.1227/NEU.0000000000000592 </plain></SENT>
</text></ref><ref id="CR33"><text><SENT sid="205" pm="."><plain>33.BijkerJBvan KleiWAVergouweYEleveldDJvan WolfswinkelLMoonsKGIntraoperative hypotension and 1-year mortality after noncardiac surgeryAnesthesiology2009111612172610.1097/ALN.0b013e3181c14930<?supplied-pmid 19934864?>19934864 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
